Last reviewed · How we verify
IDE161
At a glance
| Generic name | IDE161 |
|---|---|
| Sponsor | IDEAYA Biosciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors (PHASE1)
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDE161 CI brief — competitive landscape report
- IDE161 updates RSS · CI watch RSS
- IDEAYA Biosciences portfolio CI